Tokyo IPO

Japanese

Chordia Therapeutics Inc.

Code Sector Market
190A Pharmaceuticals Growth
Date of listing approval 2024/05/10
Expected Date 2024/06/14
Lead Underwriter SBI SECURITIES Co.,Ltd.    
Description  
Listed Shares(total) 10,465,000
Trading Unit 100
New Shares 9,100,000
Existing Shares 1,365,000¡Êonly O.A.¡Ë
Shares Outstanding PreIPO 56,443,800.00
PostIPO 65,543,800.00
Paid Up Capital PreIPO Y90,000,000
PostIPO Y659,205,288
Expected Pricing Date 2024/05/28
Book Building Start 2024/05/30
Book Building End 2024/06/05
Fix Date 2024/06/06
Offering Starts 2024/00/7
Offering Ends 2024/06/12
Expect Pricing Y143-Y153
Notional PER
(based on previous period)
36.11-38.64
Notional PER(based on results forecast) -3.54--3.79
Offering Price Y153
Offering Price PER
(based on previous period)
-3.54--3.79
Offering Price PBR
(based on previous period)
1.93
Offering Price PER
(based on results forecast)
-3.79
Use of Funds Raised  

Financial Data

Units:Y1,000

Fiscal Year End:2021/08
Consolidated Non-consolidated
Revenue - 800,000
Current Profit - -525,207
Net Profit - -527,107
Net Assets - 2,056,435
Fiscal Year End:2022/08
Consolidated Non-consolidated
Revenue -
Current Profit - -1,776,640
Net Profit - -1,779,060
Net Assets - 4,277,539
Fiscal Year End:2023/08
Consolidated Non-consolidated
Revenue - 2,500,000
Current Profit - 225,761
Net Profit - 223,341
Net Assets - 4,500,881
Recent Quarter
2024/02
Consolidated Non-consolidated
Revenue -
Current Profit - -801,401
Net Profit - -802,611
Net Assets - 3,698,270
Results Forecast
2024/08
Consolidated Non-consolidated
Revenue -
Current Profit - -2,278,000
Net Profit - -2,280,000
Net Assets - -

Per Share Units:Y1

Fiscal Year End:2021/08
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity -15.08 -58.19
Fiscal Year End:2022/08
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity -39.78 -72.35
Fiscal Year End:2023/08
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -
Equity 3.96 79.28
Fiscal Year End:Interim Results
2024/02
Consolidated Non-consolidated
Dividend  
Net Earning - -14.22
Equity - -
Fiscal Year End:Results Forecast
2024/08
Consolidated Non-consolidated
Dividend 0.00
Net Earning - -40.40
Equity - -

Comment

¢£Over allotment(1,365,000)

Consolidated Subsidiaries

Name Address

Underwriters

Allocation Underwriter Tel
0% Nomura 03-3211-1811
85% SBI SECURITIES Co.,Ltd. 03-5562-7210
5% Nomura 03-3211-1811
5% Mizuho 03-5208-3210
0.5% Akatsuki Securities 03-5641-7800
0.5% IwaiCosmo Securities Co.,Ltd. 06-6229-2890
0.5% Okasan 03-3272-2211
0.5% Kyokuto 03-3667-9171
0.5% Toyo 03-5117-1040
0.5% Hirota 06-6201-1181
0.5% Matsui 03-5216-0606
0.5% Marusan 03-3272-5211
0.5% Mito 03-6739-0310
0.5% Rakuten Securities 03-6406-2681

Data

Date of incorporation 2017/10/12
Company address  Kanagawa 251-0012
Telephone 03-6661-9543
President  
Homepage https://www.chordiatherapeutics.com/
Auditor Azsa
Major Shareholders
Shareholder Name Ratio
86.62%
  14.71%
  12.38%
  10.27%
  7.86%
  7.18%
  6.55%
  6.19%
  6.12%
  5.24%
  4.14%
Number of Employees 21 as of 2024/03/31
Birth Date of Representative 1970/06/25

Comment